NephroPlus (Nephrocare Health Services) is the largest dialysis network in India and Asia, operating 550 clinics across 357 cities as of June 2026, with a presence in India, Philippines, Uzbekistan, Saudi Arabia, and Kazakhstan (subsidiary incorporated). The company generates revenue per treatment (RPT) that varies sharply by geography: India at roughly $22, Philippines at $111, and Uzbekistan at $60, with international operations now contributing about 45% of revenue, up from 30% a year and a half ago. The business model is asset-light in the sense that it partners with hospitals (captive units), runs standalone clinics, and operates PPPs, with a focus on chronic dialysis. Adjusted EBITDA margin stood at 23.1% in Q1 FY27 (up 120 bps YoY), and adjusted PAT margin at 13.1%, reflecting strong operating leverage and pricing power. The competitive structure is fragmented: 80% of India's dialysis capacity is unorganized, and NephroPlus holds roughly 50% of the organized market, making it a consolidator in a niche with high barriers.
The persistence of these economics rests on several durable barriers. First, scale and focus: the company was PAT negative for 13 years before turning profitable, and its 100% dedication to dialysis allows it to achieve cost advantages through global procurement, an in-house biomedical team, and training academies (NIDA's first batch begins in Q3 FY27). Second, switching costs are high: hospital partners outsource dialysis because they do not make money on it, and NephroPlus has a captive renewal rate of over 95%, with PPP renewals near 100%. Third, regulatory complexity in markets like the Philippines (multiple licenses, annual renewals) deters new entrants, and the company's culture and clinical outcomes are hard to replicate. These are not commodity economics; they are niche dominance with a clear moat.
The inflection point is the international expansion, particularly Saudi Arabia. The first clinic at Riyadh Hospital became operational in July 2026, and home dialysis has commenced, but the large Ministry of Health and Ministry of Defense tender is still at the EOI stage, moving to RFP in the coming quarters. Over the next 18-24 months (by mid-2028), the company expects to add 40-50 clinics per year in India and 10-15 in the Philippines, while entering a new international market every 12-18 months (Kazakhstan is already being explored). With 550 clinics now, the network could reach 650-700 clinics by mid-2028. International mix is likely to exceed 50% of revenue, lifting blended RPT and margins. The company has guided to a 15-20% revenue CAGR over 3-4 years, and with FY26 revenue of roughly INR 1,000 crore (based on 38.4 lakh treatments at INR 2,598 RPT), FY28 revenue could be in the INR 1,320-1,440 crore range. Capex is accelerating: INR 165 crore in FY26, with Q1 FY27 alone at INR 44 crore, and the company has INR 500 crore in cash to fund growth.
Management has consistently reaffirmed the 15-20% revenue CAGR guidance across the Feb, May, and Aug 2026 calls, and has delivered on key milestones. In Q1 FY27, they added 26 clinics (19 in India, 7 in the Philippines), expanded into 17 new Indian cities, and grew active guests by 13% YoY to 38,262. Adjusted EBITDA grew 30.7% to INR 65.1 crore, and adjusted PAT grew 41.7% to INR 37 crore. The Saudi clinic launch came within the two-month window promised in May 2026. They have also been disciplined on capital allocation, exiting two value-dilutive Uttarakhand PPP clinics and focusing on return thresholds. Working capital improved, with AR days down from 121 to 101 YoY. The only deviation was a one-time ECL provision of INR 10 crore in Q4 FY26, which temporarily depressed margins to 20.9%, but excluding that, the margin was 25%. This walk-talk record supports confidence in the guidance.
Earnings visibility is high because growth is driven by same-clinic ramp-up (patient additions and modest price increases) and clinic roll-ups, which are predictable. The 15-20% CAGR implies a clear earnings path: with adjusted EBITDA margin around 23-24% and PAT margin around 13%, FY28 adjusted PAT could be in the INR 170-190 crore range. The key assumption is that the Saudi investment phase does not drag margins beyond the expected 100-150 bps dip, and that the tender converts. The single most important watchpoint is the Saudi tender timeline and outcome, which is binary (win or exit the market) and currently 3-4 quarters away. If the tender is delayed or lost, the investment phase could persist, but the company has a track record of executing on clinic additions and margin improvement. The tension between near-term margin pressure from Saudi and the underlying operational improvement is resolved by the fact that Q1 FY27 margins were already up 120 bps YoY, indicating that the core business is strong enough to absorb the investment phase. The falsifier would be a sustained margin decline below 20% or a failure to win the Saudi tender, which would force a reassessment of the international growth story.
companyname: Nephrocare Health Services Limited ticker: NEPHROPLUS sector: Dialysis / Kidney Care Services NephroPlus is a dialysis service provider. When both kidneys fail, a patient needs dialysis or a transplant to survive, and dialysis is a fixed, recurring treatment: three sessions a week, each roughly 4.5 hours including pre- and post-treatment time, for life. The company was founded in 2010 in Hyderabad by Vikram Vuppala and Kamal Shah. Shah has been on dialysis himself for more than 28 ...
Read the full report →capex, margin expansion, geographic expansion, acquisition inorganic
FY27-29 revenue CAGR guided at 15-20% over 3-4 years
Guidance maintainedGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Nephrocare Health Services Ltd and 4,900+ companies.
5-day free pass. No card required.